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Summary Knowledge of the factors determining the performance of bronchodilator
reversibility testing in a general population is lacking. Random samples of all adults
aged 47–48 and 71–73 years living in Bergen, Norway, were invited to a cross-
sectional study. Altogether 3506 subjects attended (69%). Test quality predictors
were examined through multiple logistic regression analyses including gender, age,
body mass, educational level, smoking history, respiratory symptoms, and in the
elderly cohort cognitive level.
Among the participants, 1.6% refused to inhale salbutamol, 2.5% failed the initial
spirometry according to the ATS guidelines, and 1.3% failed the post-bronchodilator
spirometry. Old age and body mass index 430 kg/m2 were independent risk factors
for an unsuccessful initial spirometry, and never smoking and respiratory symptoms
were risk factors for failing the post-bronchodilator spirometry. Cognitive impair-
ment in the elderly was a risk factor for failing both the initial- and post-
bronchodilator spirometry. The median number of forced expirations was 7 in
subjects obtaining an acceptable reversibility test. One third of these participants
needed X8 attempts, with independent predicting factors being old age, little
formal education and never smoking.
Although reversibility testing becomes increasingly difficult with age, reliable data
are obtained in a vast majority (94%) of subjects in our community study.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
The bronchodilator reversibility test result (i.e. the
difference in FEV1 before and after adrenergic b2-
agonist inhalation) has traditionally been useful in
differentiating between COPD and asthma, in
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guiding treatment, in establishing best attainable
lung function, and thereafter in predicting the
patient’s prognosis.1 The post-bronchodilator FEV1
has a greater predictive value on survival in
subjects with obstructive lung disease than the
pre-bronchodilator value.2–5 According to the
NHLBI/WHO Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD), the prevalence of
spirometric defined COPD should be obtained after
bronchodilatation.1
The success rate of simple spirometry in studies
of general populations6–9 depends on anthropo-
metric variables, smoking history, respiratory
symptoms, and bronchial hyperresponsiveness.
Nevertheless, there is limited knowledge on the
factors determining performance of the reversibil-
ity test in a community study.10,11 Neither the
fraction of subjects excluded due to unacceptable
spirometry performance in a bronchodilatation
setting, nor the willingness to inhale an adrenergic
b2-agonist have been reported.
In this cross-sectional population study of
middle-aged and elderly women and men, the
objectives were; (1) to estimate the success rate of
the adrenergic reversibility test using simple
spirometry equipment, (2) to identify predictors
of test failure and (3) to assess the need for
additional spirometric attempts by anthropometric
variables, smoking history, educational level, cog-
nitive function, and respiratory symptoms and
disorders.
Methods
Population
The target population included all women and men
born between 1925–1927 and 1950–1951 living in
the municipality of Bergen from 31 December 1992,
who participated in a health study12 (n ¼ 7949;
attendance rate: 67%). In 1998 an age–gender
stratified random sample of 510 persons was
selected from each of the 10 age–gender groups
in the follow-up study, among persons still alive and
living in Bergen (n ¼ 7456). The 5100 subjects
received a postal questionnaire and an invitation
to be reversibility-tested. Those who did not meet
for the testing received one reminder after 3
weeks. Neither patients who had inhaled a bronch-
odilator prior to test nor subjects with other
diseases were excluded from the study. The study
protocol was approved by the Regional Ethics
Committee as well as the Norwegian Data Inspec-
torate.
Technician and spirometry quality control
and reversibility testing
One technician, well trained in the spirometric
procedures, supervised 99.7% of the tests. Forced
expirations were recorded with two dry wedge
spirometers (Vitalograph S-model).7,13 The
spirometers were calibrated to 7 l each morning
of the 198 study days, using the same 1 l precision
syringe. The calibration results of the two spirom-
eters varied between 7.00 l and 7.10 l. Daily
biological control measurements of FVC and
FEV1 were recorded in 4 persons. The coefficient
of variation (CV¼ 100 SD/mean) for FEV1 and
FVC in the biological controls were 3.7%
(range 3.2–4.4) and 3.3% (range 3.0–3.6), respec-
tively.
Before each spirometric examination, the tech-
nician explained the performance of the maneuver,
and a five-point instruction was read by the
participant. Due to a possible risk of worsening in
patients with unstable asthma, abstinence from
bronchodilators prior to spirometry was not re-
quired. However, all participants were asked if they
had inhaled adrenergic bronchodilators within 6 h
before spirometry.1,14
The spirometric measurements were carried out
with the subject sitting upright with a noseclip,
ensuring that the subject produced the highest
possible peak flows. To obtain an optimal effort,
the subject was enthusiastically coached during
forced expirations. End-of-test criterion was de-
fined as a forced exhalation time of at least 6 s or
an obvious plateau with no volume increase for
at least 1 s in volume–time curves without
artifacts, and with the two highest FEV1 and
FVC values reproducible within 200ml.15 After
baseline spirometry, 0.4mg of salbutamol
powder was inhaled from a discus inhaler.16 The
subjects inhaled two doses of 0.2mg, and per-
formed two inhalation procedures for each dose.
Any discomfort reported by the participants
after inhalation of salbutamol was recorded as
possible side effects. The post-bronchodilator
spirometry should be executed 15min after inhala-
tion of salbutamol powder, and the time lag
from the start of salbutamol inhalation to the
start of the second spirometry was recorded.
Each subject performed up to eight forced expira-
tions before and eight forced expirations after
inhalation of salbutamol, until three acceptable
spirograms before and after bronchodilatation
were obtained. The three highest pre- and post-
bronchodilatation measurements of FVC with their
corresponding FEV1 were manually recorded to
nearest 50ml.
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Surveillance of procedure and records
Acceptable spirograms were ascertained by the
technician, who also counted the number of forced
expirations. All spirometric recordings were proof-
read by one of two physicians. The outcome of each
subjects test performance was coded into accep-
tance or failure. Failure was defined as either (1)
left the testing room before spirometry; (2)
incorrect pre-bronchodilatation spirometry record;
(3) refused inhalation of salbutamol or (4) incorrect
post-bronchodilatation spirometry record.
Mini mental status, height and weight
measurements
Structured Mini Mental Status Examination (MMSE)
interviews17 were conducted on the elderly cohort
before reversibility testing. A MMSE sumscore of
10–12 was considered as normal and o10 as
cognitive dysfunction. Height was measured to
the nearest cm and weight to the nearest 0.5 kg,
and the participants were grouped into those with
body mass index (BMI) o25 kg/m2, X25 kg/m2
(overweight) and 430 kg/m2 (obese).18
Questionnaires
Self-administered questionnaires were applied on
educational level,19 seven respiratory symp-
toms,20,21 physician’s diagnosis of obstructive lung
diseases22 and smoking habits.23 These questions
have been validated in Norwegian popula-
tions.20,24,25
Data management and statistical analyses
Statistical analyses were performed using Statisti-
cal Package for the Social Sciences versions 10.0
and 11.0 (SPSS Inc., Chicago, Illinois). Continuous
data are presented as means (7 standard devia-
tion). Two-sided Fisher’s exact test was used to
assess differences in participation rates and out-
come of reversibility testing by gender, age
cohorts, groups with different smoking history,
educational background and respiratory symptoms.
Gender differences in attendance by pack-years
were analyzed by Student’s two-sample t-test.
Multiple logistic regression analysis was used for
binominal outcome variables (i.e. correct vs.
incorrect performance of reversibility test before
and after inhalation of salbutamol, and if in need of
spirometric attempts in the upper tertial (X 8) vs.
less attempts). All odds ratios (OR) were adjusted
for age, gender, educational level, smoking history,
respiratory symptoms and BMI. Cognitive level (i.e.
MMSE) was added to the regression model for the
elderly cohort. Covariates were grouped and are
represented in the model as categorical indicator
variables to assess non-linearity. Trend tests were
performed to assess possible linear dose-response
relations. A P-value of less than 0.05 (two-sided
test) was considered statistically significant.
Results
Population
The main characteristics of the participants by
gender and age are presented in Table 1.
The attendance rate did not differ by gender
(70% women and 68% men, P ¼ 0:10), but it was
higher in the middle-aged compared with the
elderly (76% vs. 64%, Po0:0001). Altogether 37%
of the participants were never smokers, 38% ex-
smokers and 23% current smokers. Among the
middle-aged, the fraction of ever-smokers did not
differ between gender. However, the male ever-
smokers reported a higher number of pack-years
compared with the women (16.0 7 9.5 vs. 12.5 7
11.8 (P ¼ 0:001). In contrast, among the elderly
almost twice as many men were ever-smokers as
the women (79% vs. 42%, P ¼ 0:001). There was no
difference in the rate of self-reported respiratory
symptoms (yes/no) between gender in any of the
two age cohorts. As expected, the elderly subjects
reported respiratory symptoms more frequently
than the middle-aged (53% vs. 41%, P ¼ 0:001). In
both cohorts, men had a higher level of education
than women (X12 years education vs. less; P ¼
0:01 in middle-aged and P ¼ 0:001 in the elderly).
Altogether, 10% of the participants were obese.
Only 2% of the elderly participants had a cognitive
dysfunction.
Factors limiting performance of the initial
spirometry
Altogether 13 (0.4%) of the participants (12 from
the elderly cohort) left the testing room after
filling out the questionnaire but before spirometry
(Table 2). No gender differences were observed
among the 88 subjects (2.5% of the participants)
who failed to obtain the initial spirometry criteria.
However, 22 persons were middle-aged and 66
persons elderly (1.4% vs. 3.4%, P ¼ 0:001). The
fraction of unacceptable pre-bronchodilator proce-
dures among the 313 subjects (9% of participants)
who reported ‘‘physician’s diagnosed obstructive
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lung disease (OLD)’’ did not differ from participants
without this diagnosis. Old age and obesity in-
creased the risk for test failure in the multiple
logistic regression analysis (Table 3). Impaired
cognitive function reduced the success rate of the
initial spirometry (OR 0.23, 95% CI 0.06–0.86)
compared to the elderly with normal function.
Factors affecting the administration of the
b2-agonist and adverse effects
Altogether, 1.6% of the participants were not
willing to inhale salbutamol. More elderly (2.4%)
than middle-aged (0.6%) (P ¼ 0:001) refused to
inhale the drug (Table 2). However, among the
elderly 6.2% had inhaled a b2-agonist within 6 h
prior to testing, compared with 2.2% of the middle-
aged (P ¼ 0:001). The fraction of successful
bronchodilator tests did not differ between those
reporting OLD who had inhaled adrenergic b2-
agonist (153) and those with OLD who had not
taken adrenergic b2-agonists (160).
Altogether, 13 persons (0.4%) reported adverse
effects after inhalation of salbutamol. Dizziness,
tremor, palpitations/tachycardia and chest discom-
fort was reported by 6, 5, 3 and 2 subjects,
respectively.
Factors limiting performance of the post-
bronchodilator study
The mean, median, and 90 percentile time lag from
first inhalation of salbutamol to start of new
spirometry was 16, 15 and 18min, respectively.
No differences were observed between gender or
between the two age cohorts.
Altogether, 45 (1.3%) subjects failed in the post-
bronchodilatation spirometry (Table 2). No gender
differences were found, but a higher proportion of
elderly performed unsatisfactory, compared with
middle-aged (1.9% vs. 0.7%, P ¼ 0:002). Subjects
with a physician’s diagnosis of OLD (n ¼ 298) had
the same rate of failure as all participants.
The multiple logistic regression analysis
(Table 3), however, showed no age differences on
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Table 1 Main characteristics of the study participants.
Gender Women Men
Age (years) 47–48 71–73 All 47–48 71–73 All
Number 823 957 1780 725 1001 1726
Smoking habits
(% of age–gender group)
Never smokers 37 57 47 34 21 26
Former smokers 27 26 27 31 62 49
Current smokers 34 14 24 33 16 23
Missing information 2 3 3 1 2 1
Respiratory symptoms
(% of age–gender group)
No 57 46 51 62 47 53
Yes 43 54 49 38 53 47
Educational level
(% of age–gender group)
0–10 years 20 44 33 15 30 24
11–12 years 44 34 39 39 42 40
X13 years 35 12 23 45 24 33
Missing information 1 11 6 1 5 4
Body mass index
(% of age–gender group) 39
o25 kg/m2 61 41 51 38 40 50
25–29.9 kg/m2 27 41 34 50 49 10
X30 kg/m2 10 17 14 10 9 2
Missing information 2 1 2 2 2
Mini mental status
(% of age–gender group)
Sumscore o10 2 2
Sumscore 10–12 81 84
Missing information 18 14
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Table 3 Risk factors for incorrect reversibility tests.
Incorrect pre-bronchodilatation proceduresn Incorrect post-bronchodilatation proceduresw
Total N n (%) Adjusted OR (95% CI) Total N n (%) Adjusted OR (95% CI)
Age
47–48 years 1547 22 (1) 1 1515 10 (1) 1
71–73 years 1946 66 (3) 2.70 (1.54–4.75) 1835 35 (2) 2.04 (0.95–4.38)
Gender
Female 1773 49 (3) 1 1690 20 (1) 1
Male 1720 39 (2) 0.72 (0.42–1.21) 1660 25 (2) 1.70 (0.84–3.44)
Smoking history
Never smokers 1288 38 (3) 1 1229 21 (2) 1
o10 packyears 697 15 (2) 1.01 (0.53–1.91) 675 9 (1) 0.84 (0.37–1.91)
10–19 packyears 577 10 (2) 0.87 (0.41–1.84) 556 4 (1) 0.29 (0.08–1.00)
20þ packyears 654 17 (3) 1.04 (0.53–2.07) 629 7 (1) 0.48 (0.19–1.23)
Education
0–10 years 979 26 (3) 1 933 18 (2) 1
11–12 years 1383 38 (3) 1.32 (0.75–2.30) 1329 15 (1) 0.71 (0.34–1.50)
X12 years 961 16 (2) 0.92 (0.45–1.89) 929 9 (1) 0.60 (0.24–1.51)
Body mass index
o25 kg/m2 1560 36 (2) 1 1505 17 (1) 1
25.0–29.9 kg/m2 1465 34 (2) 0.99 (0.58–1.70) 1403 20 (1) 1.08 (0.53–2.22)
X30 kg/m2 410 15 (4) 1.94 (1.00–3.78) 388 8 (2) 1.51 (0.59–3.84)
Respiratory symptoms
No 1821 53 (3) 1 1740 13 (1) 1
Yes 1672 35 (2) 0.70 (0.42–1.15) 1610 32 (2) 2.30 (1.13–4.70)
Multiple logistic regression analysis on age, gender, education, smoking habits, body mass index, and respiratory symptoms.
nSubjects who left the testing room before spirometry (n ¼ 13) were excluded from the pre-bronchodilatation spirometry
analysis.
wSubjects who performed technically incorrect prebronchodilator spirometry (n ¼ 88), refused inhalation of salbutamol
(n ¼ 55), or had left the testing room before spirometry (n ¼ 13) were excluded from the post-bronchodilatation spirometry
analysis.
Table 2 Causes of test failure within the four age–gender groups in persons with and without obstructive lung
disease.n
Subjects with known obstructive Subjects without known obstructive Total
lung disease lung disease
Gender Women Men Subtotal Women Men Subtotal
Age (years) 47–48 71–73 47–48 71–73 47–48 71–73 47–48 71–73
Numbers 66 90 46 111 313 757 867 679 890 3193 3506
Left the testing
room before
spirometry
F F F F F 1
(0.1%)
6
(1%)
F 6
(1%)
13
(0.4%)
13
(0.4%)
Incorrect pre-
bronchodilatation
spirometry record
1
(2%)
2
(2%)
F 3
(3%)
6
(2%)
12
(2%)
34
(4%)
9
(1%)
27
(3%)
82
(3%)
88
(3%)
Refused inhalation
of salbutamol
F 3
(3%)
F 6
(5%)
9
(3%)
7
(1%)
24
(2%)
3
(0.4%)
12
(1%)
46
(1%)
55
(2%)
Incorrect post-
bronchodilatation
spirometry record
F 1
(1%)
1
(2%)
2
(2%)
4
(1%)
3
(0.4%)
16
(2%)
6
(1%)
16
(2%)
41
(1%)
45
(1%)
ni.e. self-reported asthma, chronic obstructive lung disease, emphysema or bronchitis treated by physician or in hospital the
last 12 months.
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the performance of the post-bronchodilator spiro-
metry. Subjects with respiratory symptoms had a
more than doubled risk (P ¼ 0:02) of test failure
compared to the asymptomatic participants.
Neither single respiratory symptoms nor ‘‘physi-
cian’s diagnosis of OLD’’ was associated with test
failure in a multiple logistic regression analysis.
Finally, never-smokers had increased risk of test
failure after salbutamol inhalation compared to the
ever-smokers (P-trend¼ 0.049).
Predictors for the number of attempts to
fulfill the test criteria
A total of 23 143 forced expiratory maneuvers were
performed by the 3305 participants with accepta-
ble reversibility testing. The mean number of
spirometric efforts was 3.8 (SD 1.1) pre- and 3.5
(SD 1.0) post-bronchodilatation. Altogether, 2/3 of
the subjects performed an acceptable reversibility
test after seven or less attempts (Fig. 1). Multiple
logistic regression analysis (Table 4) showed that
the elderly cohort compared to the middle-aged
(P ¼ 0:001), never-smokers compared to ever-smo-
kers (P-trend¼ 0.003), and little educated com-
pared to highly educated subjects (P-trend¼ 0.002)
were at risk of X8 attempts. In the elderly cohort,
individuals with no respiratory symptoms compared
to the symptomatic subjects (P ¼ 0:025), and
participants with cognitive dysfunction compared
to those with a normal cognitive level (P ¼ 0:018)
were at increased risk of needingX8 attempts for a
successful reversibility test. When educational
level and MMSE were added to the multiple logistic
regression analyses separately, high values of both
variables were associated with o8 attempts.
However, the association between high educational
level and fewer spirometric attempts was not
present after adjustment for cognitive level.
Discussion
While previous studies have examined performance
of spirometry, this is the first study to assess success
rate and further characteristics of the reversibility
test. In this cross-sectional population study of
middle-aged and elderly, 94% met the test criteria.
Older age and obesity were independent risk
factors for an unsuccessful performance of the
initial spirometry. Risk factors for failing the post-
bronchodilator spirometry were never smoking and
respiratory symptoms. Older age, lower educa-
tional level, and never smoking were predictors for
belonging to the upper tertile needing 8 or more
spirometric attempts for a successful reversibility
test. Furthermore, in the elderly cohort, cognitive
impairment was a risk factor for failure of both the
initial- and post-bronchodilator spirometry. How-
ever, one technician supervised almost all proce-
dures, and therefore we have no information on
possible technician related within-subject variabil-
ity in acceptable spirometry performance.26
Selection bias in attendance may affect our
results. An equal number of subjects from each
birth year and gender were invited, but response
rates were higher in the middle-aged cohort
compared with the elderly, giving less confidence
of the results in the latter group. However, a
recently published cohort study from the same
community27 has shown that an increase in re-
sponse rate from 65% to 89% gave unchanged
incidence of respiratory disorders and associations
with risk factors. Nevertheless, lower attendance
rate in the oldest cohort might lead to an under-
estimation of the effects of age and reduced
cognitive function on spirometric performance.
To avoid a possible worsening of patient’s
respiratory condition, the participants were not
asked to refrain from bronchodilators. Still, there
are questions to be asked on the consequences of
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Figure 1 Distribution of subjects demanding 6 to 16 forced expirations for an acceptable bronchodilatation test.
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demanding abstinence from bronchodilators prior
to reversibility testing, such as: How many more
would have followed this request, and what would
have been the consequences for those in need of
these drugs?
Spirometry in elderly subjects had a higher rate
of non-acceptable and -reproducible maneuvers,
compared with middle-aged adults as in the US
NHANES III6 and the 6-Cities study.9 Similarly, Bellia
et al.28 identified higher age, cognitive impairment
and lower educational level as risk factors for a
poorer reproducibility of FEV1 in a case–control
study in Italy of elderly COPD and asthma patients.
In a Norwegian community survey of middle-aged
men,7 overweight was associated with failing the
1993 European Community for Coal and Steel
acceptability criteria. This observation was con-
firmed for obese men as well as women in the
present study. Obesity is a known risk factor for
variable airflow limitations.29 Congestive heart
failure is common in the elderly, and is, like
asthma, associated with bronchial hyperrespon-
siveness.30 Bronchial hyperresponsiveness was the
most important determinant of spirometric test
failure in the study of 20–45 years old women and
men by Ng’ang’a and coworkers.8
In agreement with the previous study in Horda-
land county,7 we found an increased post-bronch-
odilatation test failure and a higher number of
spirometric attempts among never smokers, com-
pared with ever smokers. Smokers with the highest
level of packyears had the lowest risk of needing
additional forced expirations. This may be due to
compression of the airways, as smokers, who
develops airflow limitation more frequently than
never smokers, produce their maximal expiratory
flow at a lower intrapleural pressure.31,32 Further-
more, many subjects with bronchial hyperrespon-
siveness would not take up smoking.33 This may
explain why smokers blow more reproducible
curves than never smokers.
Similar to the 6-Cities study of a general
population,9 we found a higher rate of spiro-
metric failure in symptomatic compared with
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Table 4 Risk factors for X 8 spirometric attempts.
X8 spirometric attempts to fulfill the ATS criteria
Total N n (%) Adjusted OR (95% CI) P valuen
Age (years)
47–48 1505 408 (27) 1
71–73 1800 674 (38) 1.46 (1.23–1.73) 0.001
Gender
Female 1670 538 (32) 1
Male 1635 544 (33) 1.14 (0.96–1.35) 0.163
Smoking history
Never smokers 1207 432 (36) 1
o10 packyears 666 197 (30) 0.75 (0.60–0.93)
10–19 packyears 552 170 (31) 0.78 (0.62–0.98)
20þ packyears 622 178 (29) 0.66 (0.52–0.83) 0.001n
Education (years)
0–10 914 348 (38) 1
11–12 1314 422 (32) 0.85 (0.70–1.03)
X12 920 253 (28) 0.69 (0.55–0.86) 0.001n
Body mass index (kg/m2)
o25 1488 457 (31) 1
25.0–29.9 1382 464 (34) 1.06 (0.89–1.26)
X30 380 139 (37) 1.28 (0.99–1.67) 0.080n
Respiratory symptoms
No 1727 570 (33) 1
Yes 1578 512 (33) 0.91 (0.77–1.08) 0.333
Multiple logistic regression analysis on age, gender, education, smoking habits, body mass index and respiratory symptoms.
nP-trend.
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asymptomatic subjects. These findings are consis-
tent with increased bronchoconstriction after
repeated forced expiratory maneuvers which occur
to a greater extent in symptomatic than in
asymptomatic subjects.34,35
Recent publications have cast doubt on the
usefulness of the reversibility testing. Although a
large response is suggestive of asthma, the test
cannot reliably distinguish asthma from COPD
unless the FEV1 value and ratio FEV1/FVC returns
to normal.36,37 In the ISOLDE study38 response to
bronchodilators or inhaled glucocorticoids could
not be predicted by the response to an adrenergic
reversibility test in patients with severe COPD.
However, this was a very selected group with an
initial FEV1 bronchodilator response o10% pre-
dicted. General practice based population screen-
ing of COPD have previously been done using both
simple spirometry and bronchodilator reversibility
testing.39,40 The majority of subjects with an
airflow limitation at initial spirometry screening
will present sub-normal lung function parameters,
values that are likely to normalize after broncho-
dilatation. Thus, bronchodilator reversibility test-
ing of all subjects eligible for screening is probably
a more specific method to identify COPD at an early
phase.
This study adds new knowledge on the factors
determining the quality of the bronchodilator test
performance among middle-aged and elderly from
a general population. Altogether, 94% of the
participants obtained an acceptable reversibility
test, and there was no difference on test perfor-
mance between subjects with- or without self-
reported obstructive lung disease. Old age and
obesity were risk factors for an unacceptable initial
spirometry. After inhalation of salbutamol, very
few side effects were reported from the partici-
pants, and predictors of test failure were never
smoking and respiratory symptoms. Predictors of
needing additional forced expirations were old age,
little formal education and never smoking. In
conclusion, the use of adrenergic reversibility
testing in a general population is a safe procedure,
and acceptable data are obtained in a vast majority
of the participants.
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